ReviewHormones & cancer2016
TERT Promoter Mutations in Thyroid Cancer.
Review in Hormones & cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review.Computational and mathematical methods in medicine · 2022Pooled it
- Synergistic role of molecular imaging and genomics in thyroid cancer management: from diagnosis to personalized treatment.Journal of translational medicine · 2026Review
- Value of TERT promoter mutations for early outcomes in papillary thyroid cancer.Endocrine-related cancer · 2026Article
- Integrating TERT promoter mutations into risk stratification of papillary thyroid cancer.Endocrine connections · 2026Article
- [Possibilities of the personalized approach to solitary thyroid nodules based on molecular profiling].Chirurgie (Heidelberg, Germany) · 2024Review
- The prognostic power of gene mutations in thyroid cancer.Endocrine connections · 2024Review
- Genomic alterations in thyroid cancer: biological and clinical insights.Nature reviews. Endocrinology · 2024Review
- The value of NGS-based multi-gene testing for differentiation of benign from malignant and risk stratification of thyroid nodules.Frontiers in oncology · 2024Article
- Anaplastic thyroid cancer: Pathogenesis, prognostic factors and genetic landscape (Review).Molecular and clinical oncology · 2023Review
- The Role of "Critical" Ultrasound Reassessment in the Decision-Making of Bethesda III Thyroid Nodules.Medicina (Kaunas, Lithuania) · 2023Article
- Collision tumor of a papillary and follicular thyroid carcinoma: a case report.Thyroid research · 2023Article
- Genetic analysis and clinicopathologic features of locally advanced papillary thyroid cancers: a prospective observational study.Journal of cancer research and clinical oncology · 2023Observational
- Mechanistic Insights of Thyroid Cancer Progression.Endocrinology · 2023Review
- InTERTwined: howCurrent opinion in endocrine and metabolic research · 2023Article
- Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer.Biomedicines · 2023Review
- Age-associated mortality is partially mediated by TERT promoter mutation status in differentiated thyroid carcinoma.PloS one · 2023Article
- TERT Promoter Mutation in Benign and Malignant Salivary Gland Tumors; A Cross-Sectional Study.Iranian journal of pathology · 2023Article
- Article
- TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea.Cancers · 2022Article
- Frequency of TERT Promoter Mutations in Real-World Analysis of 2,092 Thyroid Carcinoma Patients.Endocrinology and metabolism (Seoul, Korea) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two mutations (C228T and C250T) in the promoter region of the telomerase reverse transcriptase (TERT) have recently been described in different types of cancer including follicular cell-derived thyroid cancer (TC). In this paper, we reviewed the rates of these mutations in different types and subtypes of TC, their association with a number of clinical and histopathological features and outcome of TC, and their potential diagnostic and prognostic roles in TC. The overall rate of these mutations in TC is about 14 % with least prevalence in the well-differentiated subtypes of papillary thyroid cancer (10-13 %). Their rates increase significantly with increasing aggressiveness of TC reaching about 40 % in the undifferentiated and anaplastic thyroid cancers. There is also clear association with increasing age of patients at the time of diagnosis of TC. The evidence is compelling but with some conflicting results for associations between TERT promoter mutations and tumor size, extrathyroidal invasion, distant metastases, high tumor TNM stage, BRAF (V600E) mutation, recurrence, and mortality. A couple of studies reported a potential diagnostic role for TERT promoter mutations in thyroid nodules with indeterminate cytology of fine needle aspiration biopsy. These studies showed 100 % specificity but very low sensitivity of 7-10 %. The sensitivity increases significantly when TERT promoter mutation testing is combined with other gene mutations, particularly BRAF (V600E) and RAS mutations. Although TERT promoter mutations seem to play significant roles in the pathogenesis of TC, the mechanisms by which they contribute to carcinogenesis remain elusive and future work is needed to fully assess the roles, interactions, and impact of these mutations on the pathogenesis, diagnosis, prognosis, and therapeutics of TC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.